Which has better valuation & earnings, HYPR or NEPH?

Nephros has higher revenue and earnings than Hyperfine. Hyperfine is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Hyperfine $11.40M 12.84 -$35.57M -$0.41 N/A Nephros $18.79M 2.09 $1.19M $0.07 51.57

Is HYPR or NEPH more profitable?

Nephros has a net margin of 4.06% compared to Hyperfine's net margin of -226.88%. Nephros' return on equity of 7.66% beat Hyperfine's return on equity. Company Net Margins Return on Equity Return on Assets Hyperfine -226.88% -98.83% -67.09% Nephros 4.06% 7.66% 5.86%

Does the media refer more to HYPR or NEPH?

In the previous week, Hyperfine had 1 more articles in the media than Nephros. MarketBeat recorded 3 mentions for Hyperfine and 2 mentions for Nephros. Nephros' average media sentiment score of 0.94 beat Hyperfine's score of 0.82 indicating that Nephros is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Hyperfine 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nephros 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, CVRX or NEPH?

Nephros has lower revenue, but higher earnings than CVRx. CVRx is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CVRx $56.65M 2.75 -$53.31M -$2.02 N/A Nephros $18.79M 2.09 $1.19M $0.07 51.57

Is CVRX or NEPH more profitable?

Nephros has a net margin of 4.06% compared to CVRx's net margin of -89.14%. Nephros' return on equity of 7.66% beat CVRx's return on equity. Company Net Margins Return on Equity Return on Assets CVRx -89.14% -120.76% -48.38% Nephros 4.06% 7.66% 5.86%

Does the media refer more to CVRX or NEPH?

In the previous week, CVRx and CVRx both had 2 articles in the media. CVRx's average media sentiment score of 0.94 equaled Nephros'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CVRx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nephros 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, NEPH or GUTS?

Nephros has higher revenue and earnings than Fractyl Health. Fractyl Health is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nephros $18.79M 2.09 $1.19M $0.07 51.57 Fractyl Health $90K 1,309.74 -$140.95M -$1.29 N/A

Is NEPH or GUTS more profitable?

Nephros has a net margin of 4.06% compared to Fractyl Health's net margin of 0.00%. Nephros' return on equity of 7.66% beat Fractyl Health's return on equity. Company Net Margins Return on Equity Return on Assets Nephros 4.06% 7.66% 5.86% Fractyl Health N/A -4,053.15% -96.41%

Does the media prefer NEPH or MBOT?

In the previous week, Microbot Medical had 1 more articles in the media than Nephros. MarketBeat recorded 3 mentions for Microbot Medical and 2 mentions for Nephros. Nephros' average media sentiment score of 0.94 beat Microbot Medical's score of 0.62 indicating that Nephros is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nephros 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Microbot Medical 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, NEPH or NNOX?

Nephros has higher revenue and earnings than Nano-X Imaging. Nano-X Imaging is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nephros $18.79M 2.09 $1.19M $0.07 51.57 Nano-X Imaging $13.02M 5.83 -$75.02M -$1.58 N/A

Is NEPH or NNOX more profitable?

Nephros has a net margin of 4.06% compared to Nano-X Imaging's net margin of -716.44%. Nephros' return on equity of 7.66% beat Nano-X Imaging's return on equity. Company Net Margins Return on Equity Return on Assets Nephros 4.06% 7.66% 5.86% Nano-X Imaging -716.44% -67.83% -59.72%

Does the media refer more to NEPH or NNOX?

In the previous week, Nano-X Imaging had 32 more articles in the media than Nephros. MarketBeat recorded 34 mentions for Nano-X Imaging and 2 mentions for Nephros. Nephros' average media sentiment score of 0.94 beat Nano-X Imaging's score of 0.06 indicating that Nephros is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nephros 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nano-X Imaging 1 Very Positive mention(s) 3 Positive mention(s) 23 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral

Nephros (NEPH) Competitors

$3.61 +0.34 (+10.40%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$3.61 0.00 (0.00%)

As of 06/26/2026 04:10 PM Eastern

Compare

NEPH vs. HYPR, CVRX, GUTS, MBOT, and NNOX

Should you buy Nephros stock or one of its competitors? MarketBeat compares Nephros with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nephros include Hyperfine (HYPR), CVRx (CVRX), Fractyl Health (GUTS), Microbot Medical (MBOT), and Nano-X Imaging (NNOX). These companies are all part of the "medical equipment" industry.

How does Nephros compare to Hyperfine?

Hyperfine (NASDAQ:HYPR) and Nephros (NASDAQ:NEPH) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

Hyperfine presently has a consensus target price of $1.78, indicating a potential upside of 20.90%. Nephros has a consensus target price of $6.00, indicating a potential upside of 66.20%. Given Nephros' stronger consensus rating and higher probable upside, analysts plainly believe Nephros is more favorable than Hyperfine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperfine	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Nephros	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Nephros has a net margin of 4.06% compared to Hyperfine's net margin of -226.88%. Nephros' return on equity of 7.66% beat Hyperfine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Hyperfine	-226.88%	-98.83%	-67.09%
Nephros	4.06%	7.66%	5.86%

15.0% of Hyperfine shares are owned by institutional investors. Comparatively, 41.1% of Nephros shares are owned by institutional investors. 26.3% of Hyperfine shares are owned by insiders. Comparatively, 6.7% of Nephros shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Nephros has higher revenue and earnings than Hyperfine. Hyperfine is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperfine	$11.40M	12.84	-$35.57M	-$0.41	N/A
Nephros	$18.79M	2.09	$1.19M	$0.07	51.57

In the previous week, Hyperfine had 1 more articles in the media than Nephros. MarketBeat recorded 3 mentions for Hyperfine and 2 mentions for Nephros. Nephros' average media sentiment score of 0.94 beat Hyperfine's score of 0.82 indicating that Nephros is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Hyperfine	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nephros	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Hyperfine has a beta of 1.38, meaning that its stock price is 38% more volatile than the broader market. Comparatively, Nephros has a beta of 1.51, meaning that its stock price is 51% more volatile than the broader market.

Summary

Nephros beats Hyperfine on 12 of the 16 factors compared between the two stocks.

How does Nephros compare to CVRx?

CVRx (NASDAQ:CVRX) and Nephros (NASDAQ:NEPH) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.

Nephros has a net margin of 4.06% compared to CVRx's net margin of -89.14%. Nephros' return on equity of 7.66% beat CVRx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CVRx	-89.14%	-120.76%	-48.38%
Nephros	4.06%	7.66%	5.86%

Nephros has lower revenue, but higher earnings than CVRx. CVRx is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CVRx	$56.65M	2.75	-$53.31M	-$2.02	N/A
Nephros	$18.79M	2.09	$1.19M	$0.07	51.57

75.3% of CVRx shares are owned by institutional investors. Comparatively, 41.1% of Nephros shares are owned by institutional investors. 13.9% of CVRx shares are owned by insiders. Comparatively, 6.7% of Nephros shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, CVRx and CVRx both had 2 articles in the media. CVRx's average media sentiment score of 0.94 equaled Nephros'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CVRx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nephros	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CVRx presently has a consensus price target of $11.50, suggesting a potential upside of 96.25%. Nephros has a consensus price target of $6.00, suggesting a potential upside of 66.20%. Given CVRx's stronger consensus rating and higher possible upside, equities analysts plainly believe CVRx is more favorable than Nephros.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CVRx	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	3.00
Nephros	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

CVRx has a beta of 0.8, meaning that its share price is 20% less volatile than the broader market. Comparatively, Nephros has a beta of 1.51, meaning that its share price is 51% more volatile than the broader market.

Summary

CVRx and Nephros tied by winning 7 of the 14 factors compared between the two stocks.

How does Nephros compare to Fractyl Health?

Nephros (NASDAQ:NEPH) and Fractyl Health (NASDAQ:GUTS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, earnings, risk and valuation.

Nephros has a beta of 1.51, suggesting that its share price is 51% more volatile than the broader market. Comparatively, Fractyl Health has a beta of 2.34, suggesting that its share price is 134% more volatile than the broader market.

Nephros has higher revenue and earnings than Fractyl Health. Fractyl Health is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nephros	$18.79M	2.09	$1.19M	$0.07	51.57
Fractyl Health	$90K	1,309.74	-$140.95M	-$1.29	N/A

Nephros has a net margin of 4.06% compared to Fractyl Health's net margin of 0.00%. Nephros' return on equity of 7.66% beat Fractyl Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nephros	4.06%	7.66%	5.86%
Fractyl Health	N/A	-4,053.15%	-96.41%

41.1% of Nephros shares are owned by institutional investors. 6.7% of Nephros shares are owned by company insiders. Comparatively, 8.5% of Fractyl Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Nephros had 1 more articles in the media than Fractyl Health. MarketBeat recorded 2 mentions for Nephros and 1 mentions for Fractyl Health. Fractyl Health's average media sentiment score of 1.87 beat Nephros' score of 0.94 indicating that Fractyl Health is being referred to more favorably in the news media.

Company	Overall Sentiment
Nephros	Positive
Fractyl Health	Very Positive

Nephros currently has a consensus target price of $6.00, indicating a potential upside of 66.20%. Fractyl Health has a consensus target price of $5.40, indicating a potential upside of 626.78%. Given Fractyl Health's higher probable upside, analysts plainly believe Fractyl Health is more favorable than Nephros.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nephros	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Fractyl Health	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Nephros beats Fractyl Health on 10 of the 16 factors compared between the two stocks.

How does Nephros compare to Microbot Medical?

Nephros (NASDAQ:NEPH) and Microbot Medical (NASDAQ:MBOT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.

In the previous week, Microbot Medical had 1 more articles in the media than Nephros. MarketBeat recorded 3 mentions for Microbot Medical and 2 mentions for Nephros. Nephros' average media sentiment score of 0.94 beat Microbot Medical's score of 0.62 indicating that Nephros is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nephros	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Microbot Medical	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nephros currently has a consensus target price of $6.00, indicating a potential upside of 66.20%. Microbot Medical has a consensus target price of $6.63, indicating a potential upside of 273.24%. Given Microbot Medical's stronger consensus rating and higher probable upside, analysts plainly believe Microbot Medical is more favorable than Nephros.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nephros	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Microbot Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

41.1% of Nephros shares are owned by institutional investors. Comparatively, 16.3% of Microbot Medical shares are owned by institutional investors. 6.7% of Nephros shares are owned by company insiders. Comparatively, 4.7% of Microbot Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Nephros has a beta of 1.51, meaning that its stock price is 51% more volatile than the broader market. Comparatively, Microbot Medical has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market.

Nephros has a net margin of 4.06% compared to Microbot Medical's net margin of 0.00%. Nephros' return on equity of 7.66% beat Microbot Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nephros	4.06%	7.66%	5.86%
Microbot Medical	N/A	-21.84%	-20.71%

Nephros has higher revenue and earnings than Microbot Medical. Microbot Medical is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nephros	$18.79M	2.09	$1.19M	$0.07	51.57
Microbot Medical	N/A	N/A	-$13.14M	-$0.26	N/A

Summary

Nephros beats Microbot Medical on 11 of the 16 factors compared between the two stocks.

How does Nephros compare to Nano-X Imaging?

Nephros (NASDAQ:NEPH) and Nano-X Imaging (NASDAQ:NNOX) are both small-cap medical equipment companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations.

Nephros has a beta of 1.51, indicating that its share price is 51% more volatile than the broader market. Comparatively, Nano-X Imaging has a beta of 1.21, indicating that its share price is 21% more volatile than the broader market.

Nephros presently has a consensus price target of $6.00, suggesting a potential upside of 66.20%. Nano-X Imaging has a consensus price target of $5.00, suggesting a potential upside of 358.72%. Given Nano-X Imaging's stronger consensus rating and higher possible upside, analysts plainly believe Nano-X Imaging is more favorable than Nephros.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nephros	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Nano-X Imaging	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	3 Strong Buy rating(s)	3.00

Nephros has higher revenue and earnings than Nano-X Imaging. Nano-X Imaging is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nephros	$18.79M	2.09	$1.19M	$0.07	51.57
Nano-X Imaging	$13.02M	5.83	-$75.02M	-$1.58	N/A

Nephros has a net margin of 4.06% compared to Nano-X Imaging's net margin of -716.44%. Nephros' return on equity of 7.66% beat Nano-X Imaging's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nephros	4.06%	7.66%	5.86%
Nano-X Imaging	-716.44%	-67.83%	-59.72%

41.1% of Nephros shares are owned by institutional investors. Comparatively, 21.5% of Nano-X Imaging shares are owned by institutional investors. 6.7% of Nephros shares are owned by company insiders. Comparatively, 7.7% of Nano-X Imaging shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Nano-X Imaging had 32 more articles in the media than Nephros. MarketBeat recorded 34 mentions for Nano-X Imaging and 2 mentions for Nephros. Nephros' average media sentiment score of 0.94 beat Nano-X Imaging's score of 0.06 indicating that Nephros is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nephros	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nano-X Imaging	1 Very Positive mention(s)	3 Positive mention(s)	23 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

Nephros beats Nano-X Imaging on 10 of the 16 factors compared between the two stocks.

Get Nephros News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NEPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NEPH vs. The Competition

Export

Metric	Nephros	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$39.19M	$8.62B	$7.04B	$12.18B
Dividend Yield	N/A	2.47%	2.66%	6.24%
P/E Ratio	51.58	16.18	26.13	24.17
Price / Sales	2.09	7.33	600.49	118.58
Price / Cash	28.78	17.79	47.95	55.62
Price / Book	3.76	3.36	10.78	6.36
Net Income	$1.19M	$226.25M	$3.58B	$337.99M
7 Day Performance	14.60%	0.41%	2.22%	0.10%
1 Month Performance	-2.43%	-3.99%	-0.09%	-1.28%
1 Year Performance	-6.48%	0.80%	34.39%	27.68%

Nephros Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NEPH Nephros	3.0974 of 5 stars	$3.61 +10.4%	$6.00 +66.2%	-6.5%	$39.19M	$18.79M	51.58	30	Gap Up High Trading Volume
HYPR Hyperfine	2.6812 of 5 stars	$1.42 +2.9%	$1.78 +25.6%	+98.9%	$140.96M	$11.40M	N/A	190	Gap Down
CVRX CVRx	3.043 of 5 stars	$4.96 -0.4%	$11.50 +131.9%	+0.7%	$131.51M	$56.65M	N/A	160	News Coverage Analyst Upgrade Gap Down
GUTS Fractyl Health	4.4237 of 5 stars	$0.82 +6.1%	$5.40 +556.1%	-54.7%	$130.57M	N/A	N/A	102	Positive News Gap Down
MBOT Microbot Medical	2.3696 of 5 stars	$1.86 +1.9%	$6.63 +257.1%	-29.0%	$123.26M	N/A	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NEPH) was last updated on 6/28/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nephros (NEPH) Competitors

NEPH vs. HYPR, CVRX, GUTS, MBOT, and NNOX

How does Nephros compare to Hyperfine?

Summary

How does Nephros compare to CVRx?

Summary

How does Nephros compare to Fractyl Health?

Summary

How does Nephros compare to Microbot Medical?

Summary

How does Nephros compare to Nano-X Imaging?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NEPH vs. The Competition

Nephros Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nephros (NEPH) Competitors

NEPH vs. HYPR, CVRX, GUTS, MBOT, and NNOX

How does Nephros compare to Hyperfine?

Do analysts rate HYPR or NEPH?

Is HYPR or NEPH more profitable?

Do institutionals and insiders have more ownership in HYPR or NEPH?

Which has better valuation & earnings, HYPR or NEPH?

Does the media refer more to HYPR or NEPH?

Which has more risk & volatility, HYPR or NEPH?

Summary

How does Nephros compare to CVRx?

Is CVRX or NEPH more profitable?

Which has better earnings and valuation, CVRX or NEPH?

Do insiders & institutionals hold more shares of CVRX or NEPH?

Does the media refer more to CVRX or NEPH?

Do analysts prefer CVRX or NEPH?

Which has more risk & volatility, CVRX or NEPH?

Summary

How does Nephros compare to Fractyl Health?

Which has more volatility & risk, NEPH or GUTS?

Which has stronger earnings & valuation, NEPH or GUTS?

Is NEPH or GUTS more profitable?

Do institutionals and insiders believe in NEPH or GUTS?

Does the media prefer NEPH or GUTS?

Do analysts prefer NEPH or GUTS?

Summary

How does Nephros compare to Microbot Medical?

Does the media prefer NEPH or MBOT?

Do analysts recommend NEPH or MBOT?

Do institutionals & insiders have more ownership in NEPH or MBOT?

Which has more volatility & risk, NEPH or MBOT?

Is NEPH or MBOT more profitable?

Which has better valuation & earnings, NEPH or MBOT?

Summary

How does Nephros compare to Nano-X Imaging?

Which has more risk & volatility, NEPH or NNOX?

Do analysts prefer NEPH or NNOX?

Which has better valuation & earnings, NEPH or NNOX?

Is NEPH or NNOX more profitable?

Do insiders & institutionals hold more shares of NEPH or NNOX?

Does the media refer more to NEPH or NNOX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NEPH vs. The Competition

Nephros Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools